Search

Displaying results 3811 - 3820 of 9670 in total
  1. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    It has since been demonstrated that the agent possesses activity against amoebas and yaws. … Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent.

  2. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

  3. Drug

    SSR-126517E

    go.drugbank.com/drugs/DB05362
    Experimental

    SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.

  4. Drug

    Poliglusam

    go.drugbank.com/drugs/DB11234
    ApprovedInvestigational

    As a rich source of dietary fiber, chitosan is used as a food ingredient or additive. … It is also reported to have an effect on protein aggregation, emulsification capacity, film-forming ability, clarifying ability, and fatty acid absorption capability [L999].

  5. Drug

    Synephrine

    go.drugbank.com/drugs/DB09203
    Investigational

    It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine. … Synephrine, also referred to as, p-synephrine, is naturally occurring alkaloid.

    Categories: Sympathomimetics Used as Decongestants
  6. Drug

    Rumex crispus pollen

    go.drugbank.com/drugs/DB10360
    Approved

    Rumex crispus pollen is the pollen of the Rumex crispus plant. Rumex crispus pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS128872, Treatment Set TS128873
  7. Drug

    Tarenflurbil

    go.drugbank.com/drugs/DB05289
    Investigational

    It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. … In June 2008 development of the drug for Alzheimer's disease was discontinued. Tarenflurbil has also been used in trials studying the treatment of Prostate Cancer.

  8. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  9. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.

  10. Target

    Lysophosphatidylcholine acyltransferase 2

    go.drugbank.com/bio_entities/BE0016122
    TargetEnzymeHumans

    (PAF) (PubMed:17182612). … Involved in platelet-activating factor (PAF) biosynthesis by catalyzing the conversion of the PAF precursor, 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) into 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine

    Synonyms: Lyso-PAF acetyltransferase, Acetyl-CoA:lyso-PAF acetyltransferase